Tag Archives: JNJ-4528

Fate Tx, Adicet Bio, and Allogene Report Clinical Updates from Allogeneic Cell Therapies; ASH 2022 Analysis 1

ASH 2022 Analysis 1: Fate Tx, Adicet Bio, and Allogene presented clinical updates from their allogeneic cell therapies in hematological malignancies. Below, Celltelligence provides insights and context for key selected presentations. The following topics are covered below:

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Thoughts on Cilta-cel’s Global Market Opportunities; Legend and JNJ’s Strategy to Position Cilta-cel in Earlier Lines of Therapy; Legend at Jefferies Cell Therapy Summit Call Summary

On Tuesday, October 6, Legend Biotech presented at the Jefferies Cell Therapy Virtual Summit (press release). Legend highlighted their clinical strategy and market opportunity for the BCMA CAR-T cilta-cel (JNJ-4528). Below, Celltelligence provides thoughts on Legend’s strategy for moving cilta-cel into earlier lines of therapy and the potential market opportunity compared to other BCMA CAR-Ts in development.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

JNJ-4528 US Filing Anticipated in Q4 2020; JNJ Q3 2020 Earnings Summary

On Tuesday, October 13, JNJ held their Q3 2020 earnings call (press release / presentation). Management reported a +13.3% WW sales growth for their oncology division, driven by their multiple myeloma product Darzalex (US +46%; WW +43.8%). Of note, JNJ confirmed that JNJ-4528 (BCMA CAR-T) is anticipated to be filed with the FDA in Q4 2020. Below, Celltelligence provides insights on a JNJ-4528 approval in 2021 and the potential impact on ide-cel (BMS) sales in the US and EU.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.